Bausch + Lomb's experimental glaucoma medication, BOL 303259-X, has shown a greater reduction of intraocular pressure than the current standard glaucoma treatment, latanoprost, according to a Medscape report.
Robert Weinreb, MD, of the University of California San Diego, presented the results of the study at the 23rd Annual American Glaucoma Society Meeting in March.
More Articles on Ophthalmology:
Dr. Christopher Calvin Brown Joins San Antonio Eye Center
Bausch + Lomb Files for Public Offering to Meet $700M Financial Obligation
Durrie Vision Helps Develop SBK LASIK
Robert Weinreb, MD, of the University of California San Diego, presented the results of the study at the 23rd Annual American Glaucoma Society Meeting in March.
More Articles on Ophthalmology:
Dr. Christopher Calvin Brown Joins San Antonio Eye Center
Bausch + Lomb Files for Public Offering to Meet $700M Financial Obligation
Durrie Vision Helps Develop SBK LASIK